MarketPeel
Insider Trading Intelligence
AY

Annie Yoshiyama

ALLO
SVP, FINANCE · ALLOGENE THERAPEUTICS, INC. · CIK 0001835208
FILING MIX · LIFETIME57%/43%
BUYS
4
SELLS
3
TOTAL VALUE
$42.8K
COMPANIES
1
ACTIVE SINCE
Jan 2025
HOLDINGS NOW
124,517
AVG SELL PX
$1.83
TRADE KIND
SHOWING 7 / 7
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 8 pending
Forward-return performance of every backtestable P/S trade by Annie Yoshiyama, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%-1.55%+2.69%-4.24%-6.68%
14d3+33.33%+7.71%+3.55%+4.16%+4.43%
30d3+66.67%-1.55%+5.97%+0.76%+0.76%
60d3+66.67%+1.82%+5.34%-3.52%-19.85%
90d3(1 pending)+50.00%+6.91%+12.80%-5.90%-5.90%
180d3(2 pending)+100.00%-13.38%+29.29%-42.67%-42.67%
1y3(2 pending)+0.00%+63.38%+37.01%+26.37%+26.37%
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ALLO · 124,517 shares · as of Apr 21, 2026
044,92389,846134,768179,6912026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
2026
FLOW · 4 buys / 3 sellsCOVERAGE · 6 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, Finance
9,586$2.31$22.1K124,517Apr 21, 2026Apr 23, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, Finance
4,167$1.72$7.2K130,322Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,82750,827Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
179,691179,691Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, Finance
9,601$1.41$13.5K130,663Apr 21, 2025Apr 23, 2025View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
128,093128,093Jan 24, 2025Jan 28, 2025View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,232137,990Jan 24, 2025Jan 28, 2025View →
Other insiders · ALLO
Loading peer insiders…
About this filer
CIK 0001835208
ROLE
SVP, Finance
PRIMARY
ALLO
COMPANIES
1
ACTIVE SINCE
Jan 2025
MARKETPEEL · /INSIDER/0001835208DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback